Mode
Home
Research
Clinical Trials Drug Pipeline Weekly Digests
Reference
Conditions Medications
Community
Questions
Text Size
Log in / Sign up
N/A N=101 Randomized Quadruple-blind Prevention

Proton Pump Inhibitor Versus Histamine-2 Receptor Antagonist for the Prevention of Recurrent Peptic Ulcers

Peptic Ulcer

Bottom Line

View on ClinicalTrials.gov: NCT02551744 ↗
Enrolled (actual)
101
Serious AEs
0.0%
Results posted
Aug 2019
Primary outcome: Primary: Number of Participants With Ulcer Recurrence — 1; 7 participants

Study Design & Population

Study type
Interventional
Phase
N/A
Interventions
histamine-2 receptor antagonist group (Drug); proton pump inhibitor group (Drug)
Age
Adult, Older Adult · 20+ yrs
Sex
All
Sponsor
Kaohsiung Veterans General Hospital.
Primary completion
Jul 2018

Outcome Measures

OutcomeResultp-value
PRIMARY
Number of Participants With Ulcer Recurrence		 1; 7 —

Summary

Whether pantoprazole versus famotidine for the prevention of recurrent peptic ulcers in thienopyridine users remains unclear.

Eligibility Criteria

Inclusion Criteria

  • Recent endoscopic examination (within 2 months) reveals normal appearance or erythematous patches only (without subepithelial hemorrhages, erosions or ulcers).
  • Peptic ulcers (a mucosal break ³ 5 mm in diameter) have been documented by a previous endoscopic examination.
  • Subjects have received thienopyridine therapy for at least two weeks.
  • Requiring long-term anti-platelet therapy for ischemic cardiovascular diseases.

Exclusion Criteria

  • A history of gastric or duodenal surgery other than oversewing of a perforation.
  • Subjects who are allergic to the study drugs.
  • Requiring long-term treatment with non-steroidal anti-inflammatory drugs (NSAIDs), corticosteroids, aspirin, or anticoagulant agents.
  • Pregnancy.
  • Subjects who have active cancer, acute serious medical illness or terminal illness.
  • Subjects who have gastroesophageal reflux disease.
View full record on ClinicalTrials.gov →

Data sourced from ClinicalTrials.gov (NCT02551744). Outcome figures and adverse-event rates are extracted automatically from the registry's posted results and are provided for clinician reference, not as a substitute for the primary publication.

Back to search